• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista Cubana de Hematología, Inmunología y Hemoterapia >Chronic myeloid leukemia treated with Imatinib Mesilate in patients resistant to or intolerant to recombinant alpha Interferon: Preliminary studies
【24h】

Chronic myeloid leukemia treated with Imatinib Mesilate in patients resistant to or intolerant to recombinant alpha Interferon: Preliminary studies

机译：甲磺酸伊马替尼治疗对重组α干扰素耐药或不耐受的慢性粒细胞白血病：初步研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Forty three patients presenting with chronic positive-Philadelphia myeloid leukemia were assessed treated with Imatinib Mesilate as a second line drug by resistance or intolerance to recombinant a Interferon. At onset, the more frequent manifestation of this condition was the splenomegalia. Imatinib Mesilate treatment was started by resistance (33; 7.6 %) or 3 or 4 degree intolerance (10; 23.3 %). The greater percentage of cytogenetic response (22; 91.7 %) and complete (11; 61.1 %) was achieved at 18 and 24 course months. The 74.3 % hadn't "molecular response and the 5.1 % yet had it before treatment; 9 (26.5 %) showed a loss of complete hematologic remission, from them, 7 deceased from disease progression. Global survival was of 90.7 %, 83.3 %, 82.6 % and 78.9 % at 5, 6, 7 and 8 course years, respectively. Global survival and free of events at three years of Imatinib Mesilate appearance was of 92.3 % and 81.8 %, respectively. There was a significant difference between survival free of events and the Sokal prognostic rate. The more frequent secondary clinical reactions were the bone and/or muscular pain and the hematologic ones were the autoimmune hemolytic anemia and the thrombocytopenia.
机译：通过对重组干扰素的抗性或不耐受性，评估了四十三名患有慢性费城髓性白血病阳性的患者，以甲磺酸伊马替尼作为二线药物对其进行了治疗。起初，这种情况最常见的表现是脾肿大。甲磺酸伊马替尼的治疗始于耐药性（33; 7.6％）或3或4度不耐受（10; 23.3％）。在18个和24个疗程月时，细胞遗传学应答的百分比更高（22; 91.7％）和完全（11; 61.1％）。 74.3％的患者没有“分子反应”，而5.1％的患者在治疗前还没有反应;其中9％（26.5％）的血液学完全消失，其中有7例因疾病进展而死亡。全球生存率为90.7％，83.3％在5、6、7和8个疗程年分别为82.6％和78.9％，甲磺酸伊马替尼出现三年的总生存率和无事件发生率分别为92.3％和81.8％。继发性临床反应是骨和/或肌肉疼痛，血液学是自身免疫性溶血性贫血和血小板减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号